• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

CCT244747 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754684

CCT244747 is a CHK1 inhibitor (IC50: 7.7nM) and also abrogates G2 checkpoint (IC50: 29nM). More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
CCT244747, Inhibitor
Full Product Name
CCT244747
Product Gene Name
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
408.46
Solubility
DMSO: 100mg/mL (244.82mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C20H24N8O2
SMILES
N#CC1=NC=C(NC2=NC=C(C3=CN(C)N=C3)C(OC)=C2)N=C1O[C@H](C)CN(C)C
CAS Number
1404095-34-6
Target & IC50
Chk1: ic50 7.7nM
In Vitro
CCT244747 (100-300mg/kg, p.o.) inhibits gemcitabine-induced pS296 CHK1 for up to 24 hours in HT29 colon tumor xenografts[1]. CCT244747 (75mg/kg, p.o.) in combination with gemcitabine has potent antitumor effects in HT29 colon tumor xenografts and Calu6 human lung cancer xenografts. CCT244747 (100mg/kg p.o., qd7d) significantly reduces tumor burden in human tumor xenografts. CCT244747 (100mg/kg, p.o.) exhibits radiosensitization activity in Cal27 xenografts [3]. CCT244747 (150mg/kg p.o.) also shows antitumor activities with irinotecan in SW620 human colon tumor xenografts [2].

Product Categories/Family for CCT244747, inhibitor

Structure of CCT244747, inhibitor

CCT244747 Inhibitor – Cat# MBS5754684

Product References and Citations for CCT244747, inhibitor

Lainchbury M, et al. Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem. 2012 Nov 26;55(22):10229-40.
Lainchbury M, et al. Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem. 2012 Nov 26;55(22):10229-40.
Walton MI, et al. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res. 2012 Oct 15;18(20):5650-61.
Walton MI, et al. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res. 2012 Oct 15;18(20):5650-61.
Patel R, et al. An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation. Radiother Oncol. 2017 Mar;122(3):470-475.
Patel R, et al. An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation. Radiother Oncol. 2017 Mar;122(3):470-475.

Other Notes

Small volumes of CCT244747, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for CCT244747 purchase

MBS5754684 is an inhibitor targeting CCT244747.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000